Articles from DeciBio Consulting

DeciBio Consulting (“DeciBio”), a precision medicine-focused strategy consulting and market intelligence firm, launched the DeciBio Market Intelligence Portal. The portal brings DeciBio’s Market Reports, DxBooks lab survey databases, Oncology Genomics Trackers, and Transcript Database into one subscription platform. It also introduces DeciChat, an AI assistant that performs cross-product querying and synthesis. Life science tools, diagnostics, and biopharma teams can ask a question and receive an answer drawn from across DeciBio’s research, with citations to the source data.

DeciBio has earned recognition in the most prominent rankings in its field: GenomeWeb, The Vault Consulting 50, and Management Consulted.

DeciBio Consulting LLC’s latest market report, “Global Clinical Oncology Biomarker Testing Market Report, Second Edition: 2023-2028,” states that the global clinical oncology biomarker testing market is predicted to reach $12.6B by 2028, driven by increased access to precision medicine therapeutics.

DeciBio Consulting LLC’s latest market report, “Digital & Computational Pathology Market Report 2023-2028,” states that the global digital pathology market, driven by continued use across pharma and increased use in clinical settings, is predicted to reach $1.75B by 2028.

DeciBio Consulting, a strategy consulting firm dedicated to accelerating the adoption and impact of precision medicine technologies, received recognition as a top consulting firm to work for in North America. DeciBio received first place in Innovation, achieving its first #1 ranking since its founding one decade ago.

DeciBio Consulting, a strategy consulting firm focused on precision medicine, was again named a top consulting firm to work for in North America. Vault.com awarded DeciBio the #30 ranking on its 2022 edition of its signature list, the Vault Consulting 50. DeciBio also advanced to #4 on Vault’s 2022 Best Boutique Consulting Firms list. DeciBio is one of the youngest firms on either list.